Clinical Trial Update: Nephrogenic Systemic Fibrosis With Gadollinum [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 trial investigating Gadollinum for Nephrogenic Systemic Fibrosis in patients with renal failure. The status of the trial is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nephrogenic Systemic Fibrosis
• Renal Failure

Drugs mentioned

• Gadollinum

Snippet

Sponsor: Imam Khomeini Hospital | Conditions: Nephrogenic Systemic Fibrosis, Renal Failure | Phase 2, Phase 3 | Status: UNKNOWN